Chronic kidney disease-mineral and bone disorder

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Retrieved on: 
Monday, September 12, 2022
Well, BMP, Alkaline phosphatase, Osteoporosis, SD, Safety, Security (finance), Lists of diseases, COVID-19, Woman, Hypertensive emergency, Part, Biomarker, Society, Growth, Intellectual property, Private Securities Litigation Reform Act, FC, Ruxolitinib, PAH, Therapy, Mouse, MDS, Haematopoiesis, U.S. Securities and Exchange Commission, Regeneration, Patient, Male, Maintenance, IIA, Protein, Bone loss, Myelodysplastic syndrome, TGF, Bone marrow, Disorder, Serum, Liver support system, KROS, Part Two, Microdeletion syndrome, Thrombocytopenia, Research, Chronic kidney disease-mineral and bone disorder, Pharmacokinetics, GLOBE, Osteogenesis imperfecta, SEC, Osteoblast, Mineral, FSH, Cytopenia, Anemia, Pharmaceutical industry, Dietary supplement, Vaccine, Medical imaging, Clinician Administered PTSD Scale, BSAP

In addition, Keros also announced preclinical data evaluating the bone anabolic activity of RKER-050, a research form of KER-050, in a mouse model of myelodysplastic syndromes (MDS).

Key Points: 
  • In addition, Keros also announced preclinical data evaluating the bone anabolic activity of RKER-050, a research form of KER-050, in a mouse model of myelodysplastic syndromes (MDS).
  • We believe these results are supportive of the potential of KER-012 to treat diseases like pulmonary arterial hypertension and bone disorders characterized by increased activin signaling.
  • Preliminary topline data from the Part 1 single ascending dose (SAD) portion of the trial was reported in May 2022.
  • As of the data cut-off date of August 4, 2022, KER-012 was generally well tolerated at all dose levels tested.

Innoskel Announces First Patient Enrolled in Observational Study to Evaluate Children Living with Type II Collagen Disorders

Retrieved on: 
Wednesday, July 13, 2022
Technology, Â, Bone, Paralysis, Biomarker, Company, Retinal detachment, Risk, Natural history, Patient, Ageing, ClinicalTrials.gov, COL2A1, Observational study, Diagnosis, Founder, Laboratory, Osteochondrodysplasia, Collection, Pain, Quality of life, Growth, Spinal fusion, Chronic kidney disease-mineral and bone disorder, Pharmaceutical industry

The study will evaluate the course of type II collagen disorders in children with short stature.

Key Points: 
  • The study will evaluate the course of type II collagen disorders in children with short stature.
  • ROCKET is an international multicenter study enrolling children aged from 0-12 years, with a confirmed diagnosis ofa type II collagen disorder.
  • Samantha Parker, Chief Patient Access Officer of Innoskel, said: It is our mission to pioneer novel treatments for people living with rare skeletal disorders.
  • Further information on the ROCKET observational study can be found on the ClinicalTrials.gov website (study identification number: NCT05408715) here .

Global Molecular Imaging Market Report to 2029 - Players Include Hologic, Hitachi, Siemens and Samsung Medison Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Biotechnology, Radiology, Health, Diagnosis, Lists of diseases, Conditional sentence, Adoption, SPECT, Hospital, Chronic kidney disease-mineral and bone disorder, Population, Urbanization, Cancer, Degenerative disease, PET/CT, Clifton Springs Hospital & Clinic, Neurological disorder, Prevalence, Molecular imaging, PET, CAGR, Microwave spectroscopy, Technology, Gamma camera, Optical flow, Government, Medical imaging, Medical device

However, continuous improvement and innovation in molecular imaging technologies and high cost of the technologies are expected to hinder the global molecular imaging market growth.

Key Points: 
  • However, continuous improvement and innovation in molecular imaging technologies and high cost of the technologies are expected to hinder the global molecular imaging market growth.
  • On the basis of technology, the global market is segmented into gamma cameras, single-photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance spectroscopy, optical imaging, and molecular ultrasound imaging.
  • It delivers improved imaging data and increases patient convenience by decreasing the scanning session count, thus PET technology dominates the global market.
  • North America dominated the global market in 2021 and is projected to maintain its domination during the forecast period.

MasterControl Recognizes EMEA Customers’ Achievements in 2022

Retrieved on: 
Tuesday, May 31, 2022
Software, Patient, International Design Excellence Awards, Health, Quality of life, Workflow, Digital transformation, Chronic kidney disease-mineral and bone disorder, Chronology, SALT, Conference, Compliance, Safety, Technology, KPI-driven code analysis, European Masters, GLOBE, Medical device

These awards recognize MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.

Key Points: 
  • These awards recognize MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.
  • The one individual award, the European Masters of Excellence Quality Champion for 2022, recognized Maria Bengzon, a software quality specialist at BONESUPPORT AB.
  • The European Masters of Excellence Awards allow us to celebrate our customers and their achievements in technology and innovation, says CEO Jon Beckstrand.
  • MasterControl Inc. is a leading provider of cloud-based quality and manufacturing software for life sciences and other regulated industries.

Bone Grafts and Substitutes Market to Expand at CAGR of 4.9% during the forecast period, TMR Report

Retrieved on: 
Thursday, April 21, 2022
Awareness, International Osteoporosis Foundation, Chronic kidney disease-mineral and bone disorder, Woman, Fracture, Allotransplantation, Incidence, Consistency, TMR, Infection, Growth, Surgeon, China Biologic Products, Man, Animal, Investment, Prevalence, Risk, Dentistry, Thermoplastic

Rising incidence of bone and joint disorders leading to continuous strides in orthopaedic surgeries is fueling the growth of the bone grafts and substitutes market.

Key Points: 
  • Rising incidence of bone and joint disorders leading to continuous strides in orthopaedic surgeries is fueling the growth of the bone grafts and substitutes market.
  • Increasing prevalence of chronic bone diseases, spurt in demand for treatment of complex bone disorders, and substantial increase in patient awareness and healthcare expenditures cements growth of the bone grafts and substitutes market.
  • Consistent R&D for improved bone grafts has led to the advent of novel biological products such as autologous, allogenic, and synthetic bone grafts.
  • Presence of modern healthcare infrastructure, evolution of bone graft and substitute products, and substantial expenditure on advanced surgical procedures fuels the growth of the bone grafts and substitutes market of the region
    Substantial R&D leading to the advent of a range of biological products such as allogenic, autologous, and synthetic bone grafts stimulates the demand in bone grafts and substitutes market
    Some of the key players operating in the bone grafts and substitutes market are;

Innoskel Appoints Dr Michel Detheux as Chairman

Retrieved on: 
Tuesday, April 12, 2022
Company, Therapy, NASDAQ, Ludwig Cancer Research, Board, Biotechnology, Research, Solvay Brussels School of Economics and Management, Board of directors, Laboratory, GlaxoSmithKline, Industry, Technology, Doctor of Philosophy, Chronic kidney disease-mineral and bone disorder, Founder, Patient, Pharmaceutical industry, Management, Biochemistry

Nice, France, 12 April 2022 Innoskel (the Company), a pioneering biotechnology company developing transformative therapies for the unmet needs of individuals with rare bone disorders, today announced the appointment of Dr Michel Detheux as Chairman of its Board of Directors, with immediate effect.

Key Points: 
  • Nice, France, 12 April 2022 Innoskel (the Company), a pioneering biotechnology company developing transformative therapies for the unmet needs of individuals with rare bone disorders, today announced the appointment of Dr Michel Detheux as Chairman of its Board of Directors, with immediate effect.
  • Dr Michel Detheux is a veteran biotech executive with over 25 years of industry experience.
  • Elvire Gouze, Chief Executive Officer and Founder of Innoskel said: We are delighted to welcome Dr Michel Detheux as Chairman.
  • Dr Michel Detheux, Chairman of Innoskel, said: Innoskel is pioneering a new approach to treating patients with rare bone disorders and I am excited to be taking on the role of Chairman at such an exciting time for the Company.

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Drug Analysis Report 2022: In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Player - ResearchAndMarkets.com

Retrieved on: 
Friday, April 1, 2022
Health, General Health, Molecule, Colorectal cancer, Cirrhosis, Therapy, Triple-negative breast cancer, Multiple myeloma, GBM, HDAC8, Disease, EC, Chronic kidney disease-mineral and bone disorder, Discovery, Central nervous system, Breast cancer, Prostate cancer, Target, R, Company, Mall of America, Alzheimer's disease, Glioblastoma, Lists of diseases, TNBC, Fibrosis, Histone

The "Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules.
  • The report outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

InnoSkel Appoints Dr Sophie Amsellem-Bosq as Chief Technical Officer

Retrieved on: 
Tuesday, December 14, 2021
Global, CTO, CMC, Solution, Company, Cell, Doctor of Pharmacy, Doctor of Philosophy, University of Paris, INSERM, Chronic kidney disease-mineral and bone disorder, Medical research, National Institute, Institute, Biotechnology, CDMO, Leadership, Paris Diderot University, Mutation, Laboratoires Servier, Gene, Technology, Pharmaceutical industry, Inserm

Nice, France, 14 December 2021 InnoSkel (the Company), a pioneering platform biotechnology company developing transformative therapies for the unmet needs of individuals with rare bone disorders, today announces the appointment of Sophie Amsellem-Bosq, PharmD, PhD as Chief Technical Officer (CTO).

Key Points: 
  • Nice, France, 14 December 2021 InnoSkel (the Company), a pioneering platform biotechnology company developing transformative therapies for the unmet needs of individuals with rare bone disorders, today announces the appointment of Sophie Amsellem-Bosq, PharmD, PhD as Chief Technical Officer (CTO).
  • Sophie has more than 20 years experience in cell and gene therapy across the entire value chain from discovery through clinical development and manufacturing, up to bedside.
  • She joins InnoSkel from advising and sharing her expertise with cell and gene therapy biotech companies and venture capital funds.
  • Sophie Amsellem-Bosq, PharmD, PhD, Chief Technology Officer at InnoSkel, added: InnoSkel is a pioneer in the development of innovative therapies for rare bone disorders.

Global Interventional Spine Devices Market Poised to Grow by $ 1.80 Bn During 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 12, 2021
Medical Devices, Health, Spine, MI, CAGR, Chronic kidney disease-mineral and bone disorder, Incidence, Growth, Bookbinding

The "Global Interventional Spine Devices Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Interventional Spine Devices Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The publisher has been monitoring the interventional spine devices market and it is poised to grow by $ 1.80 bn during 2021-2025, decelerating at a CAGR of 7.40% during the forecast period.
  • Their report on the interventional spine devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The interventional spine devices market analysis includes the procedure segment and geographic landscape.

Action for bone health is needed now more than ever, urges IOF

Retrieved on: 
Wednesday, October 20, 2021
Man, Pain, Infarction, Woman, Bone fracture, Risk, World Osteoporosis Day, Spine, Osteoporosis, Chronic kidney disease-mineral and bone disorder, Disability, Fracture, Nutrient, Hip, International Osteoporosis Foundation, WOD, IOF, Ageing, Disease, Calcium, Cardiovascular disease, Vitamin D, Hospital, Map, Patient, Major, Cholesterol, Stroke, COVID-19, Dietary supplement, Dentistry

Worldwide, osteoporosis-related fractures affect up to one in three women and one in five men aged 50 years and over.

Key Points: 
  • Worldwide, osteoporosis-related fractures affect up to one in three women and one in five men aged 50 years and over.
  • IOF President Professor Cyrus Cooper noted:
    "The pandemic's continuing toll on bone health and the timely delivery of osteoporosis assessment and care is of global concern.
  • Given this backdrop, it is more important than ever to be proactive on behalf of bone health.
  • Such life-changing injuries can be prevented with life-long attention to bone health, and early diagnosis and appropriate treatment for those at risk."